CAS 868540-17-4

General Information

Carfilzomib is indicated for relapsed or refractory multiple myeloma in adults who have received 1-3 lines of therapy in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.

About the API

Trade name(s) Kyprolis
Technology Peptide
Therapeutic category Oncology
Available formulations Injectables
Regulations US DMF Flag US DMF